

Directional dominance on stature and cognition in diverse human populations

A list of authors and their affiliations appears in the online version of the paper

Homozygosity has long been associated with rare, often devastating, Mendelian disorders¹, and Darwin was one of the first to recognize that inbreeding reduces evolutionary fitness². However, the effect of the more distant parental relatedness that is common in modern human populations is less well understood. Genomic data now allow us to investigate the effects of homozygosity on traits of public health importance by observing contiguous homozygous segments (runs of homozygosity), which are inferred to be homozygous along their complete length. Given the low levels of genome-wide homozygosity prevalent in most human populations, information is required on very large numbers of people to provide sufficient power^{3,4}. Here we use runs of homozygosity to study 16 health-related quantitative traits in 354,224 individuals from 102 cohorts, and find statistically significant associations between summed runs of homozygosity and four complex traits: height, forced expiratory lung volume in one second, general cognitive ability and educational attainment ($P < 1 \times 10^{-300}$, 2.1×10^{-6} , 2.5×10^{-10} and 1.8×10^{-10} , respectively). In each case, increased homozygosity was associated with decreased trait value, equivalent to the offspring of first cousins being 1.2 cm shorter and having 10 months' less education. Similar effect sizes were found across four continental groups and populations with different degrees of genome-wide homozygosity, providing evidence that homozygosity, rather than confounding, directly contributes to phenotypic variance. Contrary to earlier reports in substantially smaller samples^{5,6}, no evidence was seen of an influence of genome-wide homozygosity on blood pressure and low density lipoprotein cholesterol, or ten other cardio-metabolic traits. Since directional dominance is predicted for traits under directional evolutionary selection⁷, this study provides evidence that increased stature and cognitive function have been positively selected in human evolution, whereas many important risk factors for late-onset complex diseases may not have been.

Inbreeding influences complex traits through increases in homozygosity and corresponding reductions in heterozygosity, most likely resulting from the action of deleterious (partially) recessive mutations⁸. For polygenic traits, a systematic association with genome-wide homozygosity is not expected when dominant alleles at some loci increase the trait value while others decrease it. Rather, dominance must be biased in one direction on average over all causal loci, for instance to decrease the trait. Such directional dominance is expected to arise in evolutionary fitness-related traits due to directional selection⁸. Studies of genome-wide homozygosity thus have the potential to reveal the non-additive allelic architecture of a trait and its evolutionary history. Historically, inbreeding has been measured using pedigrees⁹. However, such techniques cannot account for the stochastic nature of inheritance, nor are they practical for the capture of the distant parental relatedness present in most modern-day populations. High-density genome-wide single nucleotide polymorphism (SNP) array data can now be used to assess genome-wide homozygosity directly, using genomic runs of homozygosity (ROH). Such runs are inferred to be homozygous-by-descent and are common in human populations^{10,11}. Summed ROH (SROH) is the sum of the length of these ROH, in megabases of DNA. F_{ROH} is the ratio of SROH to the

total length of the genome. Like pedigree-based F (with which it is highly correlated³), F_{ROH} estimates the probability of being homozygous at any site in the genome. F_{ROH} has been shown to vary widely within and between populations¹² and is a powerful method of detecting genome-wide homozygosity effects¹³.

We found marked differences by geography and demographic history in both the population mean SROH and the relationship between SROH and NROH (the numbers of separate runs of homozygosity) (Fig. 1). As observed previously^{3,12,14}, isolated populations have a higher burden of ROH, whereas African heritage populations have the least homozygosity.

We studied $\beta_{F_{ROH}}$, defined as the effect of F_{ROH} on 16 complex traits of biomedical importance (Fig. 2). For height, FEV1 (forced expiratory volume in one second, a measure of lung function), educational attainment, and g (a measure of general cognitive ability derived from scores on several diverse cognitive tests), we found the effect sizes were greater than two intra-sex standard deviations, with P values all less than 10^{-5} . Thus the associations could not plausibly be explained by chance alone (Table 1; see Extended Data Figs 1–4 for Forest plots of individual traits; Supplementary Table 1 for s.d.). To ensure that the results were not driven by a few outliers, we repeated the analysis excluding extreme sub-cohort trait results. In all cases the effect sizes and their significance remained similar or increased (see Supplementary Table 2 for comparisons with and without outliers). After exclusion of outliers, these effect sizes translate into a reduction of 1.2 cm in height and 137 ml in FEV1 for the offspring of first cousins, and into a decrease of 0.3 s.d. in g and 10 months' less educational attainment.

We performed a number of analyses to exclude confounding. While SROH is wholly a genetic effect, its inheritance is entirely non-additive. Therefore, unlike in genome-wide association, an association with population genetic structure or co-segregation of additive genome-wide polygenic effects and SROH (as opposed to SNPs in a genome-wide association study) are not expected as a matter of course, except in the case of siblings. However, confounding could still theoretically arise, as discussed below. We therefore assessed this by conducting stratified and covariate analyses. We found effects of similar magnitude and in the same direction for all four traits across isolated and non-isolated European, Finnish, African, Hispanic, East Asian and South and Central Asian populations (Extended Data Fig. 5a and Supplementary Table 3). We further tested whether the effect sizes were similar when cohorts were split into more and less homozygous groups. The effect sizes were very similar, even though the degree of homozygosity (and variation in homozygosity) varied 3–10-fold between the two strata (depending on which cohorts contributed to the trait; Extended Data Fig. 5b). This suggests a broadly linear relationship with SROH. In general, confidence intervals overlap for stratified estimates, suggesting that differences arose due to sampling variance. Larger confidence intervals for some estimates reflect the lower power of some strata, in turn reflecting the sample size and degree of homozygosity of those strata (for example, the wider confidence intervals for estimates of educational attainment $\beta_{F_{ROH}}$ for Finnish and African strata). Finally, we fitted educational attainment




Figure 1 | Runs of homozygosity by cohort. The sum of runs of homozygosity (SROH) and the number of runs of homozygosity (NROH) are shown by sub-cohort. Populations differ by an order of magnitude in their mean burden of ROH. There are clear differences by continent and population type both in the mean SROH, and the relationship between SROH and NROH. S.C. Asian, South and Central Asian; E. Asian, East Asian; Eur. Isolate, European isolates. The ten most homozygous cohorts are labelled: AMISH, Old Order Amish from Lancaster County, Pennsylvania; HUTT, Schmiedeleut Hutterites from South Dakota; NSPHS, northern Swedish population health study, 06 and 09 suffixes are different sampling years from different counties in northern Sweden; OGP, Ogliastra genetic park, Sardinia, Italy; Talana is a particular village in the region; FVG, Friuli-Venezia-Giulia genetic park, Italy, omni and 370 suffixes refer to subsets genotyped with the Illumina OmniX and 370CNV arrays; HELIC, Hellenic isolates, Greece, from Pomak villages in Thrace, and CLHNS, Cebu Longitudinal Health and Nutrition Survey in the Philippines.

as a proxy for potential confounding by socio-economic status; this covariate was available in sufficient (47) cohorts to maintain power. The estimated effect sizes for height, FEV1 and g all reduced (17%, 18% and 35%, respectively, Extended Data Fig. 5c), but this might have been expected given the known covariance between these three traits and educational attainment, and the association we found between educational attainment and F_{ROH} . We found very small differences (3–11% reductions) in estimated $\beta_{F_{ROH}}$ (Extended Data Fig. 6 and Supplementary Table 4), when comparing the fitting of polygenic mixed models as opposed to fixed-effect-only models, again suggesting that confounding (in this case due to polygenic effects arising from recent common ancestry) did not substantially affect the results.

Despite the observed 17–35% reductions in estimated effect sizes for F_{ROH} on height, FEV1 and g , when fitting educational attainment as a covariate, the persistence of an effect suggests that most of the signals we observe are genetic. The consistency of effects with and without fitting relatedness and in particular in populations with very different degrees of homozygosity, all appear inconsistent with confounding as a result of environmental or additive genetic effects. As does the broad similarity in effect sizes across continents, although the relatively smaller numbers of cohorts of non-European descent meant we had limited power to detect intercontinental differences in effect sizes.

It is also interesting to consider the potential influence of assortative mating, which is commonly observed for human stature, cognition and education. The phenotypic extremes could be more genetically similar to each other and hence the offspring more homozygous, even if the highly polygenic trait architectures reduce this effect. However, at




Figure 2 | Effects of genome-wide homozygosity, $\beta_{F_{ROH}}$, on 16 traits. Four phenotypes show a significant effect of burden of ROH: height (145 sub-cohorts), FEV1 (34), educational attainment (47) and general cognitive ability, g (23). HDL and total cholesterol are not significantly different from zero after correcting for 16 tests and no effect is observed for the other traits. To account for the different numbers of males and females in cohorts and marked effect of sex on some traits, trait units are intra-sex standard deviations. $\beta_{F_{ROH}}$ is the estimated effect of F_{ROH} on the trait, where F_{ROH} is the ratio of the SROH to the total length of the genome. 95% confidence intervals are also plotted. Plus signs indicate that the phenotype was rank transformed, asterisks indicate that the phenotype was log transformed. BMI, body mass index; BP, blood pressure; FP fasting plasma; HbA1c, haemoglobin A1c (glycated haemoglobin); FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HDL, high density lipoprotein; LDL, low density lipoprotein.

least in its simplest balanced form, the increase in genetic similarity would be equal at both ends of the phenotypic distribution, leading to no linear association between such genetic similarity and the trait; both tall and short people would be more homozygous. Furthermore, humans also mate assortatively on the basis of body mass index, for which we see no effect. A more complex possibility, a form of reverse causality, could arise when subjects from one trait extreme (for example, people with high educational attainment) are on average more geographically mobile, and thus have less homozygous offspring, with those offspring in turn inheriting the trait extreme concerned¹⁵. We do not think that this mechanism can account for our results, since it does not readily explain the constancy of our results under different models, especially the similarity in $\beta_{F_{ROH}}$ for either more or less homozygous populations. Moreover, we observe similar effects in multiple single-village cohorts, and the Amish and Hutterites, where there is no geographic structure and/or no sampling of immigrants, hence such confounding by differential migration cannot occur.

Table 1 | Effects of genome-wide burden of runs of homozygosity on four traits

Phenotype	Outliers	Height	FEV1 ⁺	Educational attainment	Cognitive ability (g) ⁺
Subjects		354,224	64,446	84,725	53,300
P-association	Included	<1 × 10 ⁻³⁰⁰	2.1 × 10 ⁻⁶	1.8 × 10 ⁻¹⁰	2.5 × 10 ⁻¹⁰
P-heterogeneity	Included	0.014	0.10	1.2 × 10 ⁻⁵	0.071
β_{F_{ROH}}-s.d.	Excluded	-2.91	-3.48	-4.69	-4.64
s.e. β_{F_{ROH}}-s.d.	Excluded	0.21	0.73	0.58	0.73
β_{F_{ROH}}-units	Excluded	-0.188	-2.2	-12.9	-4.64
s.e. β_{F_{ROH}}-units	Excluded	0.014	0.46	1.83	0.73
Units		m	litres	years	s.d.
First cousin offspring effect	Excluded	-1.2	-137	-9.7	-0.29
Units		cm	ml	months	s.d.

P-association is the *P* value for association; P-heterogeneity is the *P* value for heterogeneity in a meta-analysis between trait and unpruned F_{ROH} ; $\beta_{F_{ROH}}$ -s.d. is the effect size estimate of F_{ROH} expressed in units of intra-sex phenotypic standard deviations; $\beta_{F_{ROH}}$ -units is the effect size estimate for $F_{ROH} = 1$ expressed in the measurement units; s.e., standard error. The *P* values for those traits showing evidence for association are calculated, including five outlying cohort-specific effect size estimates (an outlier was defined as *t*-test statistic over 3 for the null hypothesis that the cohort effect size estimate equals the meta-analysis effect size estimate), which is conservative, as the majority of these are in the opposite direction. However, β estimates exclude these outliers, for which there is evidence of discrepancy, and should thus be more accurate. A plus symbol indicates that the phenotype was rank transformed; FEV1 is forced expiratory lung volume in one second; general cognitive ability is calculated as the first unrotated principal component of test scores across diverse domains of cognition.

Our estimate for the effect of homozygosity in height is consistent with previous work: genomic⁴ and pedigree¹⁶ studies have shown genome-wide homozygosity effects on stature with similar effect sizes (a 0.01 increase in *F* decreases height by 0.037 s.d.¹⁶ versus 0.029 s.d. in the present study). We speculate that homozygosity is acting on a shared endophenotype of torso size which we detect in the height and FEV1 traits. The fact that the FEV1:FVC (forced vital capacity) ratio is not associated with ROH points to the effect acting on lung/chest size rather than airway calibre. The cognition effects cannot be wholly generated by height as an intermediate cause, given the greater proportion of variance explained for cognition, although we note that the correlation between height and cognition has been estimated as 0.16 (standard error, s.e. = 0.01), and the genetic correlation (the correlation in additive genetic values) as 0.28 (s.e. = 0.09; ref. 17).

Height is the canonical human complex trait, highly heritable and polygenic, with 697 genome-wide significant variants in 423 loci explaining 20% of the heritability and all common variants predicted to explain 60% of the heritability¹⁸. Most of the genetic architecture appears to be additive in nature, however ROH analysis reveals a distinct directional dominance component.

Our genomic confirmation of directional dominance for *g* and discovery of genome-wide homozygosity effects on educational attainment in a wide range of human populations adds to our knowledge of the genetic underpinnings of cognitive differences, which are currently thought to be largely due to additive genetic effects¹⁹. Our findings go beyond earlier pedigree-based analyses of recent consanguinity to demonstrate that the observed effect of genome-wide homozygosity is not a result of confounding and influences demographically diverse populations across the globe. The estimated effect size is consistent with pedigree data (a 0.01 increase in *F* decreases *g* by 0.046 s.d. in our analysis and 0.029–0.048 s.d. in pedigree-based studies)²⁰. It is germane to note that one extreme of cognitive function, early onset cognitive impairment, is strongly influenced by deleterious recessive loci²¹, so we can speculate that an accumulation of recessive variants of weaker effect may influence normal variation in cognitive function. Although increasing migration and panmixia have generated a secular trend in decreasing homozygosity²², the Flynn effect, wherein succeeding generations perform better on cognitive tests than their predecessors²³, this cannot be explained by our findings, because the intergenerational change in cognitive scores is much larger than the differences in homozygosity would predict. Likewise, the genome-wide homozygosity effect on height cannot explain a significant proportion of the observed intergenerational increases²⁴.

Inbreeding depression, which arises from the effect of genome-wide homozygosity, is ubiquitous in plants and is seen for numerous fitness-related traits in animals²⁵, but we observed no effect for the 12 other mainly cardio-metabolic traits in which variation is strongly related to age. This suggests that previous reports in ecological studies or

substantively smaller studies using pedigrees or relatively small numbers of genetic markers may have been false positives^{5,6}. The lack of directional dominance on these traits does not, however, rule out a recessive component, as recessive variants acting in different directions will cancel out. Dominance variance is predicted to be greater for late-onset fitness traits²⁶, so the lack of genome-wide homozygosity effects in the cardio-metabolic traits may be due to lack of directional dominance. ROH analyses within specific genomic regions are warranted to map recessive effects even when there is no genome-wide directional dominance. Such recessive effects have been observed for a subset of cardiovascular risk factors²⁷ and expression traits²⁸.

We have demonstrated the existence of directional dominance on four complex traits (stature, lung function, cognitive ability and educational attainment), while showing any effect on another 12 health-related traits is at least almost an order of magnitude smaller, non-linear or non-existent. This directional dominance implies that size and cognition (like schizophrenia protective alleles²⁹) have been positively selected in human history – or at least that some variants increasing these traits contribute to fitness. However, the lack of any evidence for an association between many late-onset cardiovascular disease risk factors and ROH is perhaps surprising and suggests testing directly for an association between ROH and disease outcome. The magnitude of genome-wide homozygosity effects is relatively small in all cases, thus Darwin's supposition³⁰ of “any evil [of inbreeding] being very small” is substantiated.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 1 February; accepted 28 May 2015.

Published online 1 July 2015.

- Garrod, A. The incidence of alkaptonuria: a study of chemical individuality. *Lancet* **160**, 1616–1620 (1902).
- Darwin, C. *The Variation of Animals and Plants Under Domestication* (Appleton, 1868).
- McQuillan, R. *et al.* Runs of homozygosity in European populations. *Am. J. Hum. Genet.* **83**, 359–372 (2008).
- McQuillan, R. *et al.* Evidence of inbreeding depression on human height. *PLoS Genet.* **8**, e1002655 (2012).
- Rudan, I. *et al.* Inbreeding and the genetic complexity of human hypertension. *Genetics* **163**, 1011–1021 (2003).
- Campbell, H. *et al.* Effects of genome-wide heterozygosity on a range of biomedically relevant human quantitative traits. *Hum. Mol. Genet.* **16**, 233–241 (2007).
- Charlesworth, D. & Willis, J. H. The genetics of inbreeding depression. *Nature Rev. Genet.* **10**, 783–796 (2009).
- Wright, S. *Evolution and the Genetics of Populations, Vol. 3: Experimental Results and Evolutionary Deductions* (University of Chicago Press, 1977).
- Wright, S. Coefficients of inbreeding and relationships. *Am. Nat.* **56**, 330–339 (1922).
- Broman, K. W. & Weber, J. L. Long homozygous chromosomal segments in reference families from the Centre d'Étude du Polymorphisme Humain. *Am. J. Hum. Genet.* **65**, 1493–1500 (1999).

11. Gibson, J., Morton, N. E. & Collins, A. Extended tracts of homozygosity in outbred human populations. *Hum. Mol. Genet.* **15**, 789–795 (2006).
12. Kirin, M. *et al.* Genomic runs of homozygosity record population history and consanguinity. *PLoS ONE* **5**, e13996 (2010).
13. Keller, M. C., Visscher, P. M. & Goddard, M. E. Quantification of inbreeding due to distant ancestors and its detection using dense single nucleotide polymorphism data. *Genetics* **189**, 237–249 (2011).
14. Pemberton, T. J. & Rosenberg, N. A. Population-genetic influences on genomic estimates of the inbreeding coefficient: a global perspective. *Hum. Hered.* **77**, 37–48 (2014).
15. Abdellaoui, A. *et al.* Educational attainment influences levels of homozygosity through migration and assortative mating. *PLoS ONE* **10**, e0118935 (2015).
16. Neel, J. V. *et al.* The effects of parental consanguinity and inbreeding in Hirado, Japan. II. Physical development, tapping rate, blood pressure, intelligence quotient, and school performance. *Am. J. Hum. Genet.* **22**, 263–286 (1970).
17. Marioni, R. E. *et al.* Common genetic variants explain the majority of the correlation between height and intelligence: the generation Scotland study. *Behav. Genet.* **44**, 91–96 (2014).
18. Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological architecture of adult human height. *Nature Genet.* **46**, 1173–1186 (2014).
19. Deary, I. J. *et al.* Genetic contributions to stability and change in intelligence from childhood to old age. *Nature* **482**, 212–215 (2012).
20. Morton, N. E. Effect of inbreeding on IQ and mental retardation. *Proc. Natl Acad. Sci. USA* **75**, 3906–3908 (1978).
21. Najmabadi, H. *et al.* Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **478**, 57–63 (2011).
22. Nalls, M. A. *et al.* Measures of autozygosity in decline: globalization, urbanization, and its implications for medical genetics. *PLoS Genet.* **5**, e1000415 (2009).
23. Flynn, J. R. Massive IQ gains in 14 nations: what IQ tests really measure. *Psychol. Bull.* **101**, 171–191 (1987).
24. Galton, F. *Natural inheritance* (MacMillan, 1889).
25. Hoffman, J. I. *et al.* High-throughput sequencing reveals inbreeding depression in a natural population. *Proc. Natl Acad. Sci. USA* **111**, 3775–3780 (2014).
26. Wright, A., Charlesworth, B., Rudan, I., Carothers, A. & Campbell, H. A polygenic basis for late-onset disease. *Trends Genet.* **19**, 97–106 (2003).
27. Weiss, L. A., Pan, L., Abney, M. & Ober, C. The sex-specific genetic architecture of quantitative traits in humans. *Nature Genet.* **38**, 218–222 (2006).
28. Powell, J. E. *et al.* Congruence of additive and non-additive effects on gene expression estimated from pedigree and SNP data. *PLoS Genet.* **9**, e1003502 (2013).
29. Keller, M. C. *et al.* Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. *PLoS Genet.* **8**, e1002656 (2012).
30. Darwin, C. *The Effects of Crossing and Self Fertilization in the Vegetable Kingdom* (John Murray, 1876).

Supplementary Information is available in the online version of the paper.

Acknowledgements This paper is the work of the ROHgen consortium. We thank the participants in all ROHgen studies; cohort-specific acknowledgements are detailed in Supplementary Table 6. This work was funded by a UK Medical Research Council (MRC) PhD studentship to P.K.J.; and J.F.W. and O.P. acknowledge support from the MRC Human Genetics Unit “QTL in Health and Disease” programme. We thank W. G. Hill for discussions and comments on the manuscript and K. Lindsay for administrative assistance.

Author contributions C.Hal., P.N., M.Me., H.B., N.J.S., D.C., D.A.M., R.S.C., P.F., G.P., S.F.G., H.H., L.F., R.A.S., A.D.M., C.N.P., G.De., P.D., L.B., U.L., S.I.B., C.M.L., N.J.T., A.Ton., P.B.M., T.I.S., C.N.R., D.K.A., A.J.O., S.L.K., B.B., G.Ga., A.P.M., J.G.E., M.J.W., N.G.M., S.C.H., J.M.S., I.J.D., L.R.G., H.T., N.Pi., J.Ka., N.J.W., L.P., J.G.W., G.Gi., M.J.C., O.R., D.D.B., C.Gi., P.v.d.H., A.A.H., P.Kr., J.S., P.Kn., M.J., P.K.M., A.H., R.Sc., I.B.B., E.Va., D.M.B., D.B., K.L.M., M.B., C.M.v.D., D.K.S., A.Te., E.Z., A.Me., P.G., S.U., C.O., D.T., G.D.S., I.R., D.J.P., M.C., T.D.S., C.Hay., J.D., R.J.L., A.F.W., G.R.C., P.V., A.Sh., P.M.R., J.I.R., N.S., U.G., K.E.N., M.P., B.M.P., D.R.W., M.La., V.G., A.Ta., J.C.C., J.S.K., D.P.S., H.C., J.N.H., M.P., O.P. and J.F.W. designed individual studies. T.N., J.D.F., S.E., V.V., S.Tr., D.I.C., S.S.N., M.Ma., D.R., A.F., L.R.Y., E.H., C.Bo., J.R.P., S.C., U.B., G.M., T.Li., I.D., J.Z., J.P.B., E.S., S.Y., M.A.A., S.J.B., G.R.B., E.P.B., A.Ca., Y. Chan, S.J.C., Y.D.I.C., F.S.C., J.C., A.Co., L.Cu., G.Da., M.D., S.B.E., B.F., M.F.F., I.F., C.S.F., T.M.F., N.Fri., F.Ge., I.Gi., O.G., F.Gr., C.Gu., C.J.H., S.E.H., N.D.H., N.L.H., K.H., L.J.H., G.Ho., P.G.H., E.I., A.J., P.J., J.J., M.Ka., S.K., S.M.K., N.M.K., H.K.K., M.Ku., J.Ku., J.L., R.A.L., T.Le., D.C.L., L.Li., M.L.L., A.Lo., T.Lu., A.Lu., S.M., K.M., J.B.M., C.Mei., T.M., C.Men., F.D.M., L.M., G.W.M., R.H.M., R.N., M.N., M.S.N., G.T.O., A.O., S.P., W.R.P., J.S.P., I.Pa., K.P., N.Po., S.Ra., P.R., S.S.R., H.R., A.R., L.M.R., R.R., B.Sa., R.M.S., V.S., A.Sa., L.J.S., S.Se., P.S., B.H.S., N.Sor., A.V.St., M.G.S., K.S., N.Ta., K.D.T., B.O.T., A.Tog., M.To., J.T., A.G.U., A.v.H.V., T.V., S.V., E.Vi., E.Vu., M.W., J.B.W., S.W., G.W., C.S.Y., G.Z., X.Z., M.Me., H.B., N.J.S., D.C., D.A.M., R.S.C., G.P., S.F.G., H.H., L.F., R.A.S., G.De., P.D., L.B., U.L., S.I.B., G.D.S., N.J.T., A.Ton., P.B.M., T.I.S., C.N.R., D.K.A., A.J.O., S.L.K., B.B., M.K.K., G.Ga., J.G.E., M.J.W., N.G.M., S.C.H., J.M.S., I.J.D., L.R.G., J.Ka., N.J.W., L.P., J.G.W., G.Gi., M.J.C., O.R., D.D.B., C.Gi., P.v.d.H., A.A.H., P.Kr., J.S., P.Kn., M.J., P.K.M., A.H., R.Sc., I.B.B., E.Va., D.M.B., D.B., K.L.M., M.B., C.M.v.D., D.K.S., E.Z., A.Me., P.G., C.O., D.T., D.J.P., M.C., T.D.S., C.Hay., R.J.L., A.F.W., G.R.C., P.V., A.Sh., P.M.R., J.I.R., N.S., U.G., M.P., B.M.P., D.R.W., M.La., J.C.C., J.S.K., D.P.S., J.N.H., M.P., O.P. and J.F.W. collected the data. S.Tr., D.I.C., M.C.C., C.Bo., U.B., I.D., M.A., F.W.A., S.J.B., D.J.B., E.B., E.P.B., A.Cc., S.J.C., J.C., I.F., T.M.F., C.Gu., C.J.H., T.B.H., N.D.H., M.I., E.I., J.J., P.Ko., M.Ku., L.J.L., R.A.L., L.Li., R.A.M., K.M., J.B.M., G.W.M., R.H.M., P.A.P., K.P., S.S.R., R.R., H.S., P.S., B.H.S., N.Sor., N.Sot., D.Va., J.B.W., C.S.Y., M.Me., N.J.S., D.C., D.A.M., R.S.C., P.F., G.P., S.F.G., H.H., L.F., G.De., P.D., L.B., U.L., S.I.B., C.M.L., A.Ton., P.B.M., C.N.R., D.K.A., A.J.O., S.L.K., B.B., G.Ga., A.P.M., M.J.W., N.G.M., S.C.H., J.M.S., I.J.D., L.R.G., J.Ka., N.J.W., L.P., M.J.C., D.D.B., P.v.d.H., P.Kr., M.J., P.K.M., A.H., R.Sc., I.B.B., D.M.B., D.B., K.L.M., M.B., C.M.v.D., D.K.S., E.Z., A.Me., P.G., S.U., C.O., I.R., D.J.P., M.C., T.D.S., C.Hay., A.F.W., G.R.C., P.V., A.Sh., P.M.R., J.I.R., N.S., U.G., K.E.N., B.M.P., D.R.W., M.La., V.G., D.P.S., H.C., O.P. and J.F.W. contributed to funding. P.K.J., T.E., H.Ma., N.E., I.Ga., T.N., A.U.J., C.Sc., A.V.Sm., W.Zhan., Y.O., A.Stc., J.D.F., W. Zhao, T.M.B., M.P.C., N.Fra., S.E., V.V., S.Tr., X.G., D.I.C., J.R.O., T.C., S.S.N., Y. Chen, M.Ma., D.R., M.Ta., A.F., T.Kac., A.Bj., A.v.d.S., Y.W., A.K.G., L.R.Y., L.W., E.H., C.A.R., O.M., M.C.C., C.P., N.V., C.Ba., A.A.A., H.R.W., D.Vu., H.Me., J.R.P., S.S.Mi., M.C.B., S.S.Me., P.A.L., G.M., A.D., L.Y., L.F.B., D.Z., P.J.v.d.M., D.S., R.M., G.He., T.Kar., Z.W., T.Li., I.D., J.Z., W.M., L.La., S.W.v.L., J.P.B., A.R.W., A.Bo., T.S.A., L.M.H., E.S., S.Y., I.M.M., L.Ca., H.G.d.H., M.A., U.A., N.A., F.W.A., S.E.B., S.B., A.Ca., Y. Chan, C.C., G.Da., G.E., B.F., M.F.F., F.Ge., M.G., S.E.H., J.J.H., J.H., J.E.H., P.G.H., A.J., Y.K., S.K., R.A.L., B.L., M.Lo., S.J.Loo., Y.L., P.M., A.Ma., C.Men., F.D.M., E.M., M.E.M., A.Mo., A.O., I.Pa., F.P., I.Pr., L.M.R., B.Sa., R.M.S., R.Sa., H.S., W.R.S., C.Sa., C.Ma., B.Se., S.Sh., S.J.Lon., J.A.S., L.S., R.J.S., M.J.S., S.Ta., B.O.T., A.Tog., M.To., N.Ts., J.v.S., S.V., D.Vo., E.B.W., W.W., J.Y., G.Z., N.J.S., R.A.S., A.D.M., C.N.P., S.I.B., N.J.T., A.P.M., S.C.H., H.T., N.Pi., L.P., P.v.d.H., P.Kr., R.Sc., I.B.B., A.Te., C.O., M.C., J.D., J.I.R., N.S., K.E.N., A.Ta., J.C.C., J.S.K. and D.P.S. analysed the data. P.K.J., T.E., H.Ma., N.E., I.Ga., T.N., A.U.J., C.Sc., A.V.Sm., M.C.B. and D.P.S. performed beta-testing of scripts. P.K.J. and T.E. performed the meta-analysis. P.K.J., T.E., O.P. and J.F.W. wrote the manuscript. All authors approved the final manuscript.

Author Information Reprints and permissions information is available at www.nature.com/reprints. Readers are welcome to comment on the online version of the paper. The authors declare competing financial interests: details are available in the online version of the paper. Correspondence and requests for materials should be addressed to J.F.W. (jim.wilson@ed.ac.uk).

METHODS

Outline. Our aim was to look for an association between a genetic effect (SROH) and 16 complex traits. Our approach followed best practice genome-wide association meta-analysis (GWAMA) protocols, where applicable, except we had only one genetic effect to test.

Cohorts were invited to join based on known previous participation in GWAMA and willingness to participate. 159 sub-cohorts were created from 102 population-based or case-control genetic studies, by separating different genotyping arrays, cases and controls or ethnic sub-groups to ensure each sub-cohort was homogeneous. Within each of the 159 sub-cohorts we measured the association between SROH and trait using the following model. Where a sub-cohort had been ascertained on the basis of a disease status associated with a particular trait, that sub-cohort was excluded from the corresponding trait analysis.

Phenotype was regressed on genetic effect and known relevant covariates within each cohort, under the model specified in equation (1). The estimated genetic effect of SROH was then meta-analysed using inverse variance meta-analysis.

$$Y = \mu + b_1 \text{ SROH} + b_2 \text{ age} + b_3 \text{ sex} + b_4 \text{ PC1} + b_5 \text{ PC2} + b_6 \text{ PC3} + e \quad (1)$$

Where Y is the vector of trait values, μ the intercept, b_1 the effect of SROH and b_2 – b_6 the effect of covariates. PC1–PC3, the post quality control within-cohort principal components of the cohort's relationship matrix and e the residual. Relationship matrices were determined genomically by each cohort using genome-wide array data. In addition, any other cohort-specific covariates known to be associated with the trait, including further principal components, and any trait-specific covariates and stratifications, such as medication and smoking status, were fitted as specified below. SROH was the sum of ROH called, with a length of at least 1.5 Mb using PLINK31.

As is routine in GWAMA, for family-based studies only, we also fitted an additive term to account for additive genetic values and relatedness, using grammar+ type residuals and full hierarchical mixed modelling using GenABEL³² and hglm³³, as specified in equation (2).

$$Y = \mu + b_1 \text{ SROH} + b_2 \text{ age} + b_3 \text{ sex} + b_4 \text{ PC1} + b_5 \text{ PC2} + b_6 \text{ PC3} + Za \quad (2)$$

Where a is the additive genetic value of each individual. Var(a) is assumed to be proportionate to the genomic relationship matrix (GRM) (a pedigree relationship matrix was used in the Framingham Heart Study). Z is the identity matrix.

We then meta-analysed the regression coefficients (b_1) of traits on SROH for the 159 sub-cohorts.

Cohort recruitment. Data from 102 independent genetic epidemiology studies of adults were included. All subjects gave written informed consent and studies were approved by the relevant research ethics committees. Homogeneous sub-cohorts were created for analysis on the basis of ethnicity, genotyping array or other factors. Where a cohort had multiple ethnicities, sub-cohorts for each separate ethnicity were created and analysed separately. In all cases individuals of European, African, South or Central Asian, East Asian and Hispanic heritage individuals were separated. In some cases sub-categories, such as Ashkenazi Jews, were also distinguished. Ethnic outliers were excluded, as were the second of any monozygotic twins and pregnant subjects. Continental ancestry of cohorts participating in each trait study is presented in Extended Data Table 1. Cohort genotyping and summary information are shown in Supplementary Table 6, with age, sex, trait and homozygosity summary statistics given in Supplementary Tables 9, 10 and 11. For case-control and trait-extreme studies, patients or extreme-only sub-cohorts were analysed separately to controls. Where case status was associated with the trait under analysis the sub-cohort was excluded from that study (see below).

Subjects within a sub-cohort were genotyped using the same SNP array, or, where two very similar arrays were used (for example, Illumina OmniExpress and IlluminaOmni1), the intersection of SNPs on both arrays, provided the intersection exceeded 250,000 SNPs. Where a study used two different genotyping arrays, separate sub-cohorts were created for each array, and analysis was done separately. Paediatric cohorts were not included.

Genotyping. All subjects were genotyped using high-density genome-wide (>250,000 SNP) arrays, from Illumina, Affymetrix or Perlegen. Custom arrays were not included. Each study's usual array-specific genotype quality control standards for genome-wide association were used and are shown in Supplementary Table 6. Only autosomal data were analysed.

Phenotyping. We studied 16 quantitative traits which are widely available and represent different domains related to health, morbidity and mortality: height, body mass index (BMI), waist:hip ratio (WHR), diastolic and systolic blood pressure (DBP, SBP), fasting plasma glucose (FPG), fasting insulin (FI), haemoglobin A1c (HbA1c), total cholesterol, HDL and LDL cholesterol levels, triglycerides, forced expiratory volume in one second (FEV1), ratio of FEV1 to forced vital

capacity (FVC), general cognitive ability (g) and years of educational attainment. Phenotypic quality control was performed locally to assess the accuracy and distribution of phenotypes and covariates. Further covariates were included when the relevant genome-wide association study consortium also included them. The trait categories were anthropometry, blood pressure, glycaemic traits, classical lipids, lung function, cognitive function and educational attainment, following models in the GIANT³⁴, ICBP³⁵, MAGIC³⁶, CHARGE³⁷, Spirometa³⁸ and SSGAC³⁹ consortia. The model for FEV1 did not include height as a covariate. Effect sizes for FEV1 therefore include size effects that also underpin height. Studies assembled files containing study traits and the following covariates: sex, age, first three principal components of ancestry, lipid-lowering medication, ever-smoker status, anti-hypertensive medication, diabetes status and year of birth. Educational attainment was defined in accordance with the ICD 1997 classification (UNESCO), leading to seven categories of educational attainment that are internationally comparable³⁹. LDL values estimated using Friedewald's equation were accepted. Cohorts without fasting samples did not participate in the LDL-cholesterol, triglycerides, fasting insulin or fasting plasma glucose analyses. Cohorts with semi-fasting samples fitted a categorical or quantitative fasting time variable as a covariate. Subjects with less than 4 h fasting were not included.

Where subjects were ascertained, for example, on the basis of hypertension, that sub-cohort was excluded from analysis of traits associated with the disorder, for example blood pressure. The traits excluded from meta-analysis are as follows: ascertainment on type 2 diabetes, thus fasting insulin, HbA1c and fasting plasma glucose excluded; ascertainment on hypertension, thus blood pressures excluded; ascertainment on venous thrombosis or coronary artery disease, thus blood lipids excluded; ascertainment on obesity or the metabolic syndrome, thus blood lipids, body mass index, waist-hip ratio, fasting insulin and fasting plasma glucose excluded.

Somewhat unusually for a large consortium meta-analysis, the majority of the analysis after initial genotype and phenotype quality control was performed by a pipeline of standardised R and shell scripts, to ensure uniformity and reduce the risk of errors and ambiguities (available at <https://www.wiki.ed.ac.uk/display/ROHgen/Analysis+Plan+production+release+3.0>). The pipeline was used for all stages from this point onwards.

Calling runs of homozygosity. SNPs with more than 3% missingness across individuals or with a minor allele frequency less than 5% were removed. ROH were defined as runs of at least 50 consecutive homozygous SNPs spanning at least 1,500 kb, with less than a 1,000 kb gap between adjacent ROH and a density of SNP coverage within the ROH of no more than 50 kb/SNP, with one heterozygote and five no calls allowed per window, and were called using PLINK³¹, with the following settings: homozyg-window-snp 50; homozyg-snp 50; homozyg-kb 1500; homozyg-gap 1000; homozyg-density 50; homozyg-window-missing 5; homozyg-window-het 1. The same criteria were used by McQuillan *et al.*³, except SNP density has been relaxed to avoid regions of sparser coverage (still including 50 SNPs) being missed. The sum of runs of homozygosity (SROH) was then calculated. F_{ROH} was calculated as $SROH/(3 \times 10^9)$ reflecting the length of the autosomal genome. Copy number variants (CNV) are known to influence cognition⁴⁰; however, prior calling of CNV and ROH in one of our cohorts reduced the SROH by only 0.3%³, making it implausible that deletions called as ROH influence our findings.

ROH called from different genotyping arrays. We show that SROH called with these parameters is relatively insensitive to the density and type of array used (Extended Data Fig. 7). We used 2.5 million SNPs available for 851 HapMap and 1000 Genomes Project⁴¹ samples from multiple continents to investigate the effect of array when using our ROH-calling parameters in PLINK. The data set included samples of African, European, admixed American, South and East Asian heritage. By subsampling SNPs from the 2.5 million we created array data for the commonly used Illumina CNV370 and OmniExpress beadchips and the Affymetrix6 array for each individual (see Supplementary Table 7 for details of the SNP numbers). The correlation in SROH using different arrays on the same individuals was 0.93–0.94 for all pairwise chip comparisons.

Trait association with SROH. The association between trait and SROH was calculated using a linear model in accordance with equation (1). Additional covariates were fitted for some analyses (shown below) or for some cohorts where analysts were aware of study specific effects (for example, study centre). For BMI, WHR, FEV1, FEV1/FVC and g, trait residuals were calculated for the model excluding SROH, these residuals were then rank-normalized and the effect of SROH on these rank-normalized residuals estimated. Triglycerides and fasting insulin were ln-transformed. Additional covariates were as follows: age² was included as a covariate for all traits apart from height and g. BMI was included as a covariate for WHR, SBP, DBP, FPG, FI and HbA1c. Year of birth was included as a covariate for educational attainment and ever-smoking for FEV1 and FEV1/FVC. Where a subject was known to be taking lipid-lowering medication, total

cholesterol was adjusted by dividing by 0.8. Similarly, where a subject was known to be taking anti-hypertensive medication, SBP and DBP measurements were increased by 15 and 10 mm Hg, respectively.

Where the cohort was known to have significant kinship, genetic relatedness was also fitted, using the mixed model, in accordance with equation (2). The polygenic model was fitted in GenABEL using the fixed covariates and the genomic relationship matrix³². GRAMMAR+ (GR+) (ref. 42) residuals were then fitted to SROH as well as the full mixed model being fitted simultaneously, using GenABEL's hierarchical generalized linear model (HGLM) function³³. Populations with kinship thus potentially had three estimates of $\beta_{F_{ROH}}$: using fixed effects only, and using the mixed model approaches, (GR+ and HGLM) for SROH.

To investigate potential confounding, where available, educational attainment was added as an ordinal covariate and all models rerun, giving revised estimates of $\beta_{F_{ROH}}$. This is potentially an over adjustment for g due to the phenotypic and genetic correlations with educational attainment⁴³. However it must be recognized that educational attainment does not capture all potential environmental confounding.

Cohort phenotypic means and standard deviations were checked visually for inter-cohort consistency, with apparent outliers then being corrected (for example, due to units or incorrectly specified missing values), explained (for example, due to different population characteristics) or excluded. Individual sub-cohort trait means and standard deviations are tabulated in Supplementary Table 9 and age and gender information is in Supplementary Table 10.

Meta-analysis. As is routine in genome-wide association meta-analyses, analysis was performed within homogeneous sub-populations and only meta-analysis of the estimated (within-population) effect sizes was used to combine results between populations, avoiding any confounding effects of inter-population differences in trait or genetic effect distributions. Inverse-variance meta-analysis of all sub-cohorts' effect estimates was performed using Rmeta, on a fixed-effect basis (Supplementary Table 5 compares random effects meta-analysis). In the principal analyses, for cohorts with relatedness, HGLM estimates of $\beta_{F_{ROH}}$ were preferred; however, where HGLM had failed to converge, results using GRAMMAR+ were included. These results were combined with those for unrelated cohorts on a fixed-model-only basis. Result outliers were defined as individual cohort by trait results, which failed the hypothesis, cohort ($\beta_{F_{ROH}} = \text{pre-quality-control meta-analysis } (\beta_{F_{ROH}})$), with a t -test statistic >3 . Analyses were performed with and without outliers for $\beta_{F_{ROH}}$ in phenotypic units and in intra-sex phenotypic standard deviations (Supplementary Table 8). The principal results we present are for F_{ROH}

with outliers included for the hypothesis tests (which turns out to be more conservative), but with outliers excluded when estimating $\beta_{F_{ROH}}$ (ref. 44). Meta-analysis was performed using inverse variance meta-analysis in the R package Rmeta, with $\beta_{F_{ROH}}$ taken as a fixed effect and alternatively as a random effect. The principal results are on a fixed-effects basis, with Supplementary Table 5 showing comparison with the random-effects analysis.

Meta-analyses were re-run for various subsets, according to geographic and demographic features of the cohorts. Cohorts were divided into more homozygous and less homozygous strata with the boundary being set so each within-stratum meta-analysis had equal statistical power.

Data reporting. Randomization and blind allocation were not applicable to this study.

31. Purcell, S. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
32. Aulchenko, Y. S., Ripke, S., Isaacs, A. & van Duijn, C. M. GenABEL: an R library for genome-wide association analysis. *Bioinformatics* **23**, 1294–1296 (2007).
33. Ronnegard, L., Shen, X. & Alam, M. hglm: a package for fitting hierarchical generalized linear models. *R Journal* **2**, 20–28 (2010).
34. Lango Allen, H. *et al.* Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature* **467**, 832–838 (2010).
35. Ehret, G. B. *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* **478**, 103–109 (2011).
36. Scott, R. A. *et al.* Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nature Genet.* **44**, 991–1005 (2012).
37. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nature Genet.* **45**, 1274–1283 (2013).
38. Soler Artigas, M. *et al.* Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nature Genet.* **43**, 1082–1090 (2011).
39. Rietveld, C. A. *et al.* GWAS of 126,559 individuals identified genetic variants associated with educational attainment. *Science* **340**, 1467–1471 (2013).
40. Stefansson, H. *et al.* CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature* **505**, 361–366 (2014).
41. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65 (2012).
42. Aulchenko, Y. S., de Koning, D. J. & Haley, C. Genomewide rapid association using mixed model and regression: a fast and simple method for genome-wide pedigree-based quantitative trait loci association analysis. *Genetics* **177**, 577–585 (2007).
43. Marioni, R. E. *et al.* Molecular genetic contributions to socioeconomic status and intelligence. *Intelligence* **44**, 26–32 (2014).
44. Hedges, L. V. & Olkin, I. *Statistical Methods for Meta-Analysis* (Academic Press, New York, 1985).

- Peter K. Joshi^{1*}, Tonu Esko^{2,3,4,5*}, Hannele Mattsson^{6,7}, Niina Eklund⁶, Ilaria Gandini⁸, Teresa Nutile⁹, Anne U. Jackson¹⁰, Claudia Schurmann^{11,12}, Albert V. Smith^{13,14}, Weihua Zhang^{15,16}, Yukinori Okada^{17,18}, Alena Stančáková¹⁹, Jessica D. Faul²⁰, Wei Zhao²¹, Traci M. Bartz²², Maria Pina Concas²³, Nora Franceschini²⁴, Stefan Enroth²⁵, Veronique Vitart²⁶, Stella Trompet²⁷, Xiuqing Guo^{28,29}, Daniel I. Chasman³⁰, Jeffrey R. O'Connell³¹, Tanguy Corre^{32,33}, Suraj S. Nongmaithem³⁴, Yuning Chen³⁵, Massimo Mangino^{36,37}, Daniela Ruggiero³⁸, Michela Traglia³⁸, Alike-Eleni Farmaki³⁹, Tim Kacprowski⁴⁰, Andrew Bjorndal⁴¹, Ashley van der Spek⁴², Ying Wu⁴³, Anil K. Giri⁴⁴, Lisa R. Yanek⁴⁵, Lihua Wang⁴⁶, Edith Hofer^{47,48}, Cornelius A. Rietveld⁴⁹, Olga McLeod⁵⁰, Marilynn C. Cornelis^{51,52}, Cristian Pattaro⁵³, Niek Verweij⁵⁴, Clemens Baumbach^{55,56,57}, Abdel Abdellou⁵⁸, Helen R. Warren^{59,60}, Dragana Vuckovic⁸, Hao Mei⁶¹, Claude Bouchard⁶², John R. B. Perry⁶³, Stefania Cappellani⁶⁴, Saira S. Mirza⁴², Miles C. Benton⁶⁵, Ulrich Broeckel⁶⁶, Sarah E. Medland⁶⁷, Penelope A. Lind⁶⁷, Giovanni Malerba⁶⁸, Alexander Drong⁶⁹, Loic Yengo⁷⁰, Lawrence F. Bielak⁷¹, Degui Zhi⁷¹, Peter J. van der Most⁷², Daniel Shriver⁷³, Reedik Mägi⁷², Gibran Hemani⁷⁴, Tugce Karaderi⁶⁹, Zhao ming Wang^{75,76}, Tian Liu^{77,78}, Ilya Demuth^{79,80}, Jing Hua Zhao⁶³, Weihua Meng⁸¹, Lazaros Latiotakis⁸², Sander W. van der Laan⁸³, Jonathan P. Bradfield⁸⁴, Andrew R. Wood⁸⁵, Amelie Bonnefond⁷⁰, Tarunveer S. Ahluwalia^{86,88,232}, Leanne M. Hall⁸⁹, Erika Salvi⁹⁰, Seyhan Yazari⁹¹, Lisbeth Carstensen⁹², Hugoline G. de Haan⁹³, Mark Abney⁹⁴, Uzma Afzal^{15,16}, Matthew A. Allison⁹⁵, Najaf Amin⁹², Folkert W. Asselbergs^{96,97,98}, Stephan J. L. Bakker⁹⁹, R. Graham Barr¹⁰⁰, Sebastian E. Baumeister¹⁰¹, Daniel J. Benjamin^{102,103}, Sven Bergmann^{103,33}, Eric Boerwinkle¹⁰⁴, Erwin P. Bottinger¹¹, Archie Campbell¹⁰⁵, Aravinda Chakravarti¹⁰⁶, Yingleong Chan^{34,5}, Stephen J. Chanock⁷⁵, Constance Chen¹⁰⁷, Y. -D. Ida Chen^{28,29}, Francis S. Collins¹⁰⁸, John Connell¹⁰⁹, Adolfo Correa⁶¹, L. Adrienne Cupples^{35,110}, George Davey Smith⁷⁴, Gail Davies^{111,112}, Marcus Dörny¹¹³, Georg Ehret^{106,114}, Stephen B. Ellis¹¹, Bjarke Feenstra⁹², Mary F. Feitosa⁴⁶, Ian Ford¹¹⁵, Caroline S. Fox^{110,116}, Timothy M. Frayling⁸⁵, Nele Friedrich¹¹⁷, Frank Geller⁹², Generation Scotland¹⁰⁵, Irina Gillham-Nasenyá³⁶, Omri Gottesman¹¹, Misa Graf²⁴, Francine Grodstein⁵², Charles H. Harles¹¹⁸, Chris Haley^{26,119}, Christopher J. Hammond³⁶, Sarah E. Harris^{105,112}, Tamara B. Harris¹²⁰, Nicholas D. Hastie²⁶, Nancy L. Heard-Costa^{110,121}, Kauko Heikkilä¹²², Lynne J. Hocking¹²³, Georg Homuth⁴⁰, Jouke-Jan Hottenga⁵⁸, Jinyuan Huang¹²⁴, Jennifer E. Huffman⁶², Pirro G. Hysi³⁶, M. Arfan Ikram^{42,125}, Erik Ingelsson^{69,126}, Anni Joensuu^{6,7}, Åsa Johansson^{25,127}, Pekka Joussilahti¹²⁸, J. Wouter Jukema¹²⁹, Mika Kähönen¹³⁰, Yoichiro Kamatani¹⁸, Stavroula Kanoni⁸², Shona M. Kerr²⁶, Nazir M. Khan⁴⁴, Philipp Koellinger⁴⁹, Heikki A. Koistinen^{131,132,133}, Manraj K. Kooper¹⁶, Michiaki Kubo¹³⁴, Johanna Kuusisto¹³⁵, Jari Lahti^{136,137}, Lenore J. Launer¹²⁰, Rodney A. Lea⁶⁵, Benjamin Lehne¹⁵, Terho Lehtimäki¹³⁸, David C.M. Liewald¹¹², Lars Lind¹³⁹, Marie Loh^{15,233}, Marja-Liisa Lokki¹⁴⁰, Stephanie J. London¹⁴¹, Stephanie J. Loomis¹⁴², Anu Loukola¹²², Yingchang Lu^{11,12}, Thomas Lumley¹⁴³, Annamari Lundqvist¹⁴⁴, Satu Männistö¹²⁸, Pedro Marques-Vidal¹⁴⁵, Corrado Masciullo³⁸, Angela Matchan¹⁴⁶, Rasika A. Mathias^{45,147}, Koichi Matsuda¹⁴⁸, James B. Meigs¹⁴⁹, Christa Meisinger⁵⁶, Thomas Meitinger^{150,151}, Cristina Menni³⁶, Frank D. Mentch⁸⁴, Evelin Mihailov⁷, Lili Milani⁷, May E. Montasser³¹, Grant W. Montgomery¹⁵², Alanna Morrison¹⁰⁴, Richard H. Myers¹⁵³, Rajiv Nadukuru¹¹, Pau Navarro²⁶, Mari Nelis⁷, Markku S. Nieminen¹⁵⁴, Ilja M. Nolte⁷², George T. O'Connor^{10,155}, Adesola Ogunniyi¹⁵⁶, Sandosh Padmanabhan¹⁵⁷, Walter R. Palmas¹⁰⁰, James S. Pankow¹⁵⁸, Inga Patarcic¹⁵⁹, Francesca Pavani⁵³, Patricia A. Peyser²¹, Kirsi Pietiläinen^{7,132,166}, Neil Poulter¹⁶¹, Inga Prokopenko¹⁶², Sarju Ralhan¹⁶³, Paul Redmond¹¹¹, Stephen S. Rich¹⁶⁴, Harri Rissanen¹⁴⁴, Antonietta Robinova⁶⁴, Lynda M. Rose³⁰, Richard Rose¹⁶⁵, Cinzia Sala³⁸, Babatunde Salako¹⁵⁶, Veikko Salomaa¹²⁸, Antti-Pekka Sarin⁶⁷, Richa Saxena⁴¹, Helena Schmidt¹⁶⁶, Laura J. Scott¹⁰, William R. Scott^{15,16}, Bengt Sennblad^{50,167}, Sudha Seshadri^{110,121}, Peter Sever¹⁶¹, Smeeta Shrestha³⁴, Blair H. Smith¹⁶⁸, Jennifer A. Smith²¹, Nicole Soranzo¹⁴⁶, Nona Sotoodehnia¹⁶⁹, Lorraine Southam^{69,146}, Alice V. Stanton¹⁷⁰, Maria G. Stathopoulou¹⁷¹, Konstantin Strauch^{57,172}, Rona J. Strawbridge⁵⁰, Matthew J. Suderman⁷⁴, Nikhil Tandon¹⁷³, Sian-Tsun Tang¹⁷⁴, Kent D. Taylor^{28,29}, Bamidele O. Tayo¹⁷⁵, Anna Maria Töglhofer¹⁶⁶, Maciej Tomaszewski^{89,176}, Natalia Tsernikova^{4,177}, Jaakko Tuomilehto^{131,178,179}, Andre G. Uitterlinden^{42,180}, Dhananjay Vaidya^{45,181}, Astrid van Hylckama Vlieg⁹³, Jessica van Setten⁸³, Tuula Vasankari¹⁸², Sailaja Vedantam^{34,5}, Efthymia Vlachopoulou¹⁴⁰, Diego Vozzi⁶⁴, Eero Vuoksimaa¹²², Melanie Waldenberger^{55,56}, Erin B. Ware²¹, William Wentworth-Shields⁹⁴, John B. Whitfield¹⁸³, Sarah Wild³⁴, Gonneke Willemssen⁵⁸, Chittaranjan S. Yajnik¹⁸⁴, Jie Yao²⁸, Gianluigi Zaza¹⁸⁵, Xiaofeng Zhu¹⁸⁶, The BioBank Japan Project¹⁸, Rany M. Salem^{34,5}, Mads Melbye^{92,187}, Hans Bisgaard⁸⁶, Nitesh J. Samani^{89,176}, Daniele Cusi⁹⁰, David A. Mackey⁹¹, Richard S. Cooper¹⁷⁵, Philippe Froguel^{70,162}, Gerard Pasternak⁸³, Struan F.A. Grant^{84,188}, Hakon Hakonarson^{84,188}, Luigi Ferrucci¹⁸⁹, Robert A. Scott⁶³, Andrew D. Morris¹⁹⁰, Colin N. A. Palmer¹⁹¹, George Dedoussis³⁹, Panos Deloukas^{82,192}, Lars Bertram^{78,193,235}, Ulman Lindenberg⁷⁷, Sonja I. Berndt⁷⁵, Cecilia M. Lindgren^{4,69}, Nicholas J. Timpson⁷⁴, Anke Tönjes³⁴, Patricia B. Munroe^{59,60}, Thorhild I. A. Sørensen^{74,88,195}, Charles N. Rotimi⁷³, Donna K. Arnett¹⁹⁶, Albertine J. Oldehinkel¹⁹⁷, Sharon L. R. Kardinaal²¹, Beverley Balkau¹⁹⁸, Giovanni Gambaro¹⁹⁹, Andrew P. Morris^{2,69,200}, Johan G. Eriksson^{128,201,202,203,204}, Margie J. Wright²⁰⁵, Nicholas G. Martin¹⁸³, Steven C. Hunt²⁰⁶, John M. Starr^{112,207}, Ian J. Deary^{111,112}, Lyn R. Griffiths⁶⁵, Henning Tiemeier^{42,208}, Nicola Pirastu^{8,64}, Jaakko Kaprio^{7,122,209}, Nicholas J. Wareham⁶³, Louis Pérusse²¹⁰, James G. Wilson²¹¹, Giorgia Grotto⁶⁷, Mark J. Caulfield^{59,60}, Olli Raitakari^{212,213}, Dorret I. Boomsma⁵⁸, Christian Gieger^{55,56,57}, Pim van der Harst^{54,97,214}, Andrew A. Hicks⁵³, Peter Kraft¹⁰⁷, Juha Sinisalo¹⁵⁴, Paul Knekt¹⁴⁴, Magnus Johannesson²¹⁵, Patrik K. E. Magnusson²¹⁶, Anders Hamsten⁵⁰, Reinhold Schmidt⁴⁷, Ingrid B. Borecki²¹⁷, Erkki Vartiainen¹²⁸, Diane M. Becker^{45,218}, Dwaipayan Bharadwaj^{44,236}, Karen L. Mohlke⁴³, Michael Boehnke¹⁰, Cornelia M. van Duijn⁴², Dharambir K. Sanghera^{219,220}, Alexander Teumer¹⁰¹, Eleftheria Zeggini¹⁴⁶, Andres Metspalu^{2,177}, Paolo Gasparini^{64,221}, Sheila Ulivi⁶⁴, Carole Ober⁹⁴, Daniela Toniolo³⁸, Igor Rudan²¹, David J. Porteous^{105,112}, Marina Ciullo⁷, Tim D. Spector³⁶, Caroline Hayward²⁶, José Dupuis^{35,110}, Ruth J. F. Loos^{11,222}, Alan F. Wright²⁶, Giriraj R. Chandak^{34,223}, Peter Vollenweider¹⁴⁵, Alan R. Shuldiner^{31,224,225}, Paul M.


Ridker³⁰, Jerome I. Rotter^{28,29}, Naveed Sattar²²⁶, Ulf Gyllenstein²⁵, Kari E. North^{24,227}, Mario Pirastu²³, Bruce M. Psaty^{228,229}, David R. Wei²⁰, Markku Laakso¹³⁵, Vilmondur Gudnason^{131,14}, Atsushi Takahashi¹⁸, John C. Chambers^{15,16,230}, Jaspal S. Meher^{16,174,230}, David P. Strachan²³¹, Harry Campbell¹, Joel N. Hirschhorn^{3,4,5}, Markus Perola^{2,6}, Ozren Polasek^{1,159*}, & James F. Wilson^{1,26*}

- ¹Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK. ²Estonian Genome Center, University of Tartu, Riia 23b, 51010, Tartu, Estonia. ³Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Cambridge, 02141 Massachusetts, USA. ⁴Program in Medical and Population Genetics, Broad Institute, Cambridge Center 7, Cambridge, Massachusetts 02242, USA. ⁵Department of Genetics, Harvard Medical School, 25 Shattuck St, Boston, Massachusetts 02115, USA. ⁶Unit of Public Health Genomics, National Institute for Health and Welfare, P.O. Box 104, Helsinki, FI-00251, Finland. ⁷Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, Helsinki, FI-00014, Finland. ⁸Department of Medical Sciences, University of Trieste, Strada di Fiume 447 - Osp. di Cattinara, 34149 Trieste, Italy. ⁹Institute of Genetics and Biophysics "A. Buzzati-Traverso" CNR, via Pietro Castellino, 111, 80131 Naples, Italy. ¹⁰Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA. ¹¹The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, USA. ¹²The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, USA. ¹³Icelandic Heart Association, Hoflasmari 1, 201, Kopavogur, Iceland. ¹⁴Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland. ¹⁵Department of Epidemiology and Biostatistics, Imperial College London, Norfolk Place, London W2 1PG, UK. ¹⁶Department of Cardiology, Ealing Hospital NHS Trust, Uxbridge Road, Southall, Middlesex UB1 3HW, UK. ¹⁷Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. ¹⁸Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan. ¹⁹Department of Medicine, University of Eastern Finland, 70210 Kuopio, Finland. ²⁰Institute for Social Research, University of Michigan, 426 Thompson Street, Ann Arbor, Michigan 48104, USA. ²¹Department of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, Michigan 48109, USA. ²²Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, Washington 98101, USA. ²³Institute of Population Genetics, National Research Council, Trav. La Crucca n. 3 - Reg. Balduca, 07100 Sassari, Italy. ²⁴Epidemiology, University of North Carolina, 137 E. Franklin St, Suite 306, Chapel Hill, North Carolina 27599, USA. ²⁵Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, SE-75108 Uppsala, Sweden. ²⁶MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, EH4 2XU Edinburgh, UK. ²⁷Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, Leiden, 2300 RC, The Netherlands. ²⁸Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, 1124 W. Carson Street, Torrance, California 90502, USA. ²⁹Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California 90502, USA. ³⁰Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue, East, Harvard Medical School, Boston, Boston, Massachusetts 02215, USA. ³¹Division of Endocrinology, Diabetes, and Nutrition and Program for Personalised and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, 685 Baltimore St. MSTF, Baltimore, Maryland 21201, USA. ³²Department of Medical Genetics, University of Lausanne, Rue du Bugnon 27, Lausanne, 1005, Switzerland. ³³Swiss Institute of Bioinformatics, Quartier Sorge - batiment génopode, Lausanne, 1015, Switzerland. ³⁴Genomic Research on Complex Diseases (GRC) Group, CSIR-Centre for Cellular and Molecular Biology, Habshiguda, Uppal Road, Hyderabad, 500007, India. ³⁵Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, Massachusetts 02118, USA. ³⁶Department of Twin Research & Genetic Epidemiology, King's College London, South Wing, Block D, 3rd Floor, Westminster Bridge Road, London SE1 7EH, UK. ³⁷NiHR Biomedical Research Centre, Guy's and St. Thomas' Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK. ³⁸Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milano, Italy. ³⁹Department of Nutrition and Dietetics, Harokopio University of Athens, 70, El. Venizelou Ave, Athens 17671, Greece. ⁴⁰Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Friedrich-Ludwig-Jahn-Str. 15A, Greifswald 17475, Germany. ⁴¹Center for Human Genetic Research, 55 Fruit Street, Massachusetts General Hospital, Massachusetts 02114, USA. ⁴²Department of Epidemiology, Erasmus Medical Center, PO Box 2040, Rotterdam, 3000 CA, The Netherlands. ⁴³Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ⁴⁴Genomics and Molecular Medicine, CSIR-Institute of Genomics & Integrative Biology, Mathura Road, New Delhi, 110025, India. ⁴⁵The GeneSTAR Research Program, Division of General Internal Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. ⁴⁶Department of Genetics, Washington University School of Medicine, 4444 Forest Park Boulevard, Saint Louis, Missouri 63108, USA. ⁴⁷Department of Neurology, Clinical Division of Neurogeriatrics, Medical University Graz, Auenbruggerplatz 22, Graz, A-8036, Austria. ⁴⁸Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Auenbruggerplatz 22, Graz, A-8036, Austria. ⁴⁹Erasmus School of Economics, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3000 DR, The Netherlands. ⁵⁰Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, CMM L8:03, Karolinska University Hospital, Solna, Stockholm, 171 76, Sweden. ⁵¹Channing Division of Network Medicine, Brigham & Women's Hospital, 181 Longwood, Boston, Massachusetts 02115, USA. ⁵²Nutrition, Harvard School of Public Health, 401 Park Drive, Boston, Massachusetts 02115, USA. ⁵³Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), 39100 Bolzano,


- Italy (affiliated Institute of the University of Lübeck, D-23562 Lübeck, Germany).
- ⁵⁴University of Groningen, University Medical Center Groningen, Department of Cardiology, Hanzplein 1, Groningen, 9700 RB, The Netherlands. ⁵⁵Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, Neuherberg 85764, Germany. ⁵⁶Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, Neuherberg 85764, Germany. ⁵⁷Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, Neuherberg 85764, Germany. ⁵⁸Department of Biological Psychology, VU University Amsterdam, Van der Boechorststraat 1, Amsterdam, 1081 BT, The Netherlands. ⁵⁹Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. ⁶⁰NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. ⁶¹Department of Medicine, University of Mississippi Medical Center, 2500 N. State St., Jackson, Mississippi 39216, USA. ⁶²Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, Louisiana 70808, USA. ⁶³MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. ⁶⁴Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", via dell'Istria 65, 34137 Trieste, Italy. ⁶⁵Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, GPO Box 2434, Brisbane Queensland 4001, Australia. ⁶⁶Dipartimento di Scienze della Vita e della Riproduzione, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy. ⁶⁷Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK. ⁶⁸CNRS UMR 8199, European Genomic Institute for Diabetics (EGID), Lille 2 University, 1 Rue du Professeur Calmette, 59000 Lille, France. ⁶⁹Department of Biostatistics, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, Alabama 35294, USA. ⁷⁰Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, P.O. box 30.001, 9700 RB, Groningen, The Netherlands. ⁷¹Center for Research on Genomics and Global Health, National Human Genome Research Institute, Building 12A/Room 4047, 12 South Dr., Bethesda, Maryland 20892, USA. ⁷²MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. ⁷³Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, Maryland 20850, USA. ⁷⁴Cancer Genomics Research Laboratory, National Cancer Institute, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA. ⁷⁵Center for Lifespan Psychology, Max Planck Institute for Human Development, Lentzeallee 94, Berlin 14195, Germany. ⁷⁶Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Ihnestr. 72, Berlin, 14195 Germany. ⁷⁷Charité Research Group on Geriatrics, Charité – Universitätsmedizin Berlin, Reinickendorferstr. 61, 13347 Berlin, Germany. ⁷⁸Institute of Medical and Human Genetics, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin 13353, Germany. ⁷⁹Division of Population Health Sciences, Medical Research Institute, University of Dundee, Ninewells Hospital and School of Medicine, Dundee DD2 4BF, UK. ⁸⁰William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. ⁸¹Experimental Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. ⁸²Center for Applied Genomics, Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA. ⁸³Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Royal Devon and Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK. ⁸⁴COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Ledreborg Allé 34, DK-2820 Copenhagen, Denmark. ⁸⁵Novo Nordisk Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, Copenhagen, 2100, Denmark. ⁸⁶Department of Cardiovascular Sciences, University of Leicester, BHF Cardiovascular Research Centre, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK. ⁸⁷Department of Health Sciences, University of Milan, via A. di Rudini 8, 20142 Milan, Italy. ⁸⁸Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute, 2 Verdun Street, Perth, Western Australia 6009, Australia. ⁸⁹Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, Copenhagen, 2300, Denmark. ⁹⁰Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, Leiden, 2300 RC, The Netherlands. ⁹¹Department of Human Genetics, University of Chicago, 920 E. 58th Street, Chicago, Illinois 60637, USA. ⁹²Department of Family and Preventive Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. ⁹³Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. ⁹⁴Durrer Centre for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Catharinesingel 52, Utrecht, 3501 DG, The Netherlands. ⁹⁵Institute of Cardiovascular Science, faculty of Population Health Sciences, University College London, Gower Street, London WC1E 6BT, UK. ⁹⁶University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Hanzplein 1, Groningen, 9700 RB, The Netherlands. ⁹⁷Department of Medicine, Columbia University, 622 W. 168th Street, New York, New York 10032, USA. ⁹⁸Institute for Community Medicine, University Medicine Greifswald, W.-Rathenau-Str. 48, Greifswald 17475, Germany. ⁹⁹Department of Economics, Cornell University, 480 Uris Hall, Ithaca, New York 14853, USA. ¹⁰⁰Department of Economics and Center for Economic and Social Research, University of Southern California, 314C Dauterive Hall, 635 Downey Way, Los Angeles, California 90089, USA. ¹⁰¹Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, 1200 Pressler Street, Suite 453E, Houston, Texas 77030, USA. ¹⁰²Centre for Genomic and Experimental Medicine, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. ¹⁰³McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. ¹⁰⁴Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, 665 Huntington Ave, Boston, Massachusetts 02115, USA. ¹⁰⁵Genome Technology Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA. ¹⁰⁶College of Medicine, Dentistry and Nursing, Ninewells Hospital and Medical School, College Office, Level 10, Dundee DD1 9SY, UK. ¹⁰⁷National Heart, Lung, and Blood Institute's Framingham Heart Study, 73 Mt. Wayte Ave, Framingham, Massachusetts 01702, USA. ¹⁰⁸Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK. ¹⁰⁹Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK. ¹¹⁰Department of Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. NK, Greifswald 17475, Germany. ¹¹¹Cardiology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil, 4, Genève 14, 1211, Switzerland. ¹¹²Robertson Centre, University of Glasgow, Boyd Orr Building, Glasgow G12 8QQ, Scotland. ¹¹³Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA. ¹¹⁴Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. NK, 17475 Greifswald, Germany. ¹¹⁵Division of Biostatistics, Washington University, 660 S Euclid, St Louis, Missouri 63110, USA. ¹¹⁶Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, Edinburgh EH25 9RG, UK. ¹¹⁷National Institutes on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. ¹¹⁸Department of Neurology, Boston University School of Medicine, 72 E Concord St, Boston, Massachusetts 02118, USA. ¹¹⁹Department of Public Health, University of Helsinki, Hjelt Institute, P.O.Box 41, Mannerheimintie 172, Helsinki, FI-00014, Finland. ¹²⁰Musculoskeletal Research Programme, Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. ¹²¹State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China. ¹²²Department of Radiology, Erasmus Medical Center, PO Box 2040, Rotterdam, 3000 CA, The Netherlands. ¹²³Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, SE-17121, Sweden. ¹²⁴Uppsala Clinical Research Center, Uppsala University, Uppsala, SE-75237, Sweden. ¹²⁵Department of Chronic Disease Prevention, National Institute for Health and Welfare, P.O. Box 30, Helsinki, FI-00271, Finland. ¹²⁶Department of Cardiology C5-P, Leiden University Medical Center, PO Box 9600, Leiden, 2300 RC, The Netherlands. ¹²⁷Department of Clinical Physiology, University of Tampere and Tampere University Hospital, P.O. Box 2000, Tampere, FI-33521, Finland. ¹²⁸Diabetes Prevention Unit, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland. ¹²⁹Department of Medicine, Division of Endocrinology, Helsinki University Central Hospital, P.O.Box 340, Haartmaninkatu 4, Helsinki, FI-00029, Finland. ¹³⁰Minerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, Helsinki, FI-00290, Finland. ¹³¹Laboratory for Genotyping Development RCMIS, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan. ¹³²Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, FI-70210, Finland. ¹³³Institute of Behavioural Sciences, University of Helsinki, P.O. Box 9, University of Helsinki, Helsinki, FI-00014, Finland. ¹³⁴Folkhälsan Research Centre, PB 63, Helsinki, FI-00014 University of Helsinki, Finland. ¹³⁵Department of Clinical Chemistry, Fimlab Laboratories and School of Medicine University of Tampere, Tampere, FI-33520, Finland. ¹³⁶Department of Medical Sciences, University Hospital, Uppsala, 75185, Sweden. ¹³⁷Transplantation laboratory, Haartman Institute, University of Helsinki, P.O. Box 21, Helsinki, FI-00014, Finland. ¹³⁸National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA. ¹³⁹Ophthalmology, Massachusetts Eye and Ear, 243 Charles Street, Boston, Massachusetts 02114, USA. ¹⁴⁰Department of Statistics, University of Auckland, 303.325 Science Centre, Private Bag 92019, Auckland, 1142, New Zealand. ¹⁴¹Department of Health, Functional Capacity and Welfare, National Institute for Health and Welfare, P.O. Box 30, Helsinki, FI-00271, Finland. ¹⁴²Department of Internal Medicine, University Hospital, Rue du Bugnon 44, Lausanne, 1011, Switzerland. ¹⁴³Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, UK. ¹⁴⁴Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA. ¹⁴⁵Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. ¹⁴⁶Division of General Internal Medicine, Massachusetts General Hospital, 50 Staniford St, Boston, Massachusetts 02114, USA. ¹⁴⁷Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, Neuherberg 85764, Germany. ¹⁴⁸Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, München 81675, Germany. ¹⁴⁹Molecular Epidemiology, QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, Queensland 4006, Australia. ¹⁵⁰Genome Science Institute, Boston University School of Medicine, 72 East Concord Street, E-304, Boston, Massachusetts 02118, USA. ¹⁵¹HUCH Heart and Lung center, Helsinki University Central Hospital, P.O. Box 340, Helsinki, FI-00029, Finland. ¹⁵²Pulmonary Center and Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, Massachusetts 02118, USA. ¹⁵³Department of Medicine, University of Ibadan, Ibadan, Nigeria. ¹⁵⁴ICAMS, University of Glasgow, 126 University Way, Glasgow G12 8TA, UK. ¹⁵⁵Division of Epidemiology and Community Health, University of Minnesota, 1300 S 2nd Street, Minneapolis, Minnesota 55454, USA. ¹⁵⁶Centre for Global Health and Department of Public Health, School of Medicine, University of Split, Soltanska 2, 21000 Split, Croatia. ¹⁵⁷Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, P.O.Box 63, Haartmaninkatu 8, FI-00014, Helsinki, Finland. ¹⁵⁸International Centre for Circulatory Health, Imperial College London, London W2 1LA, UK. ¹⁵⁹Department of Genomics of Common Disease, School of Public Health, Imperial College London, London SW7 2AZ, UK. ¹⁶⁰Department of Cardiology and Cardiothoracic Surgery Hero DMC Heart Institute, Civil Lines, 141001, Ludhiana, India. ¹⁶¹Department Public Health Sciences, University of Virginia School of Medicine, 3232 West Complex, Charlottesville, Virginia 22908, USA. ¹⁶²Department of Psychological & Brain Sciences, Indiana University Bloomington, 1101 E. 10th Street, Bloomington, Indiana 47405, USA. ¹⁶³Institute of Molecular Biology and Biochemistry, Medical University Graz,

Harrachgasse 21, Graz, A-8010, Austria. ¹⁶⁷Science for Life Laboratory, Karolinska Institutet, Stockholm, SE-17121, Sweden. ¹⁶⁸University of Dundee, Kirsty Semple Way, Dundee DD2 4DB, UK. ¹⁶⁹Cardiovascular Health Research Unit, Division of Cardiology, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, Washington 98101, USA. ¹⁷⁰Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland. ¹⁷¹UMR INSERM U1122: IGE-PCV "Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire", INSERM, University of Lorraine, 30 Rue Lionnois, 54000 Nancy, France. ¹⁷²Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Munich 81377, Germany. ¹⁷³Department of Endocrinology, All India Institute of Medical Sciences, Ansari Nagar East, New Delhi, 110029, India. ¹⁷⁴National Heart and Lung Institute, Imperial College London, Du Cane Road, London W12 0NN, UK. ¹⁷⁵Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, USA. ¹⁷⁶NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK. ¹⁷⁷Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu, 51010, Estonia. ¹⁷⁸Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria. ¹⁷⁹Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia. ¹⁸⁰Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, Rotterdam, 3000 CA, The Netherlands. ¹⁸¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. ¹⁸²Finnish Lung Health Association, Sibeliuksenkatu 11 A 1, Helsinki, FI-00250, Finland. ¹⁸³Genetic Epidemiology, QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, Queensland 4006, Australia. ¹⁸⁴Diabetes Unit, KEM Hospital and Research Centre, Rasta Peth, Pune, 411011, India. ¹⁸⁵Renal Unit, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37124 Verona, Italy. ¹⁸⁶Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio 44106, USA. ¹⁸⁷Department of Medicine, Stanford University, 300 Pasteur Drive, Stanford, California 94305, USA. ¹⁸⁸Department of Pediatrics, Perelman School of Medicine, The University of Pennsylvania, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA. ¹⁸⁹Translational Gerontology Branch, National Institute on Aging, Baltimore, Maryland 21225, USA. ¹⁹⁰Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, No. 9 Edinburgh Bioquarter, 9 Little France Road, Edinburgh EH16 4UX, UK. ¹⁹¹Centre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, University of Dundee, Ninewells Hospital and School of Medicine, Dundee DD1 9SY, UK. ¹⁹²Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, 21589, Saudi Arabia. ¹⁹³Faculty of Medicine, Imperial College London, Charing Cross Campus, St Dunstan's Road, London W6 8RP, UK. ¹⁹⁴Department of Medicine, University of Leipzig, Leipzig 04103, Germany. ¹⁹⁵Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, 2000, Denmark. ¹⁹⁶Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, Alabama 35294, USA. ¹⁹⁷Department of Psychiatry, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, Groningen, 9700 RB, The Netherlands. ¹⁹⁸Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, Inserm, CESP Center for Research in Epidemiology and Population Health U1018, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif, France. ¹⁹⁹Dipartimento di Scienze Mediche, Catholic University of the Sacred Heart, Via G. Moscati 31/34, 00168 Roma, Italy. ²⁰⁰Department of Biostatistics, University of Liverpool, Duncan Building, Daulby Stree, Liverpool L69 3GA, UK. ²⁰¹Department of General Practice and Primary Health Care, University of Helsinki, P.O. Box 20, University of Helsinki, Helsinki, FI-00014, Finland. ²⁰²Vasa Central Hospital, Sandviksgatan 2-4, Vasa, FI-65130, Finland. ²⁰³Folkhälsan Research Centre, PB 63, University of Helsinki, Helsinki, FI-00014, Finland. ²⁰⁴Unit of General Practice, Helsinki University Central Hospital, Haartmaninkatu 4, Helsinki, FI-00290, Finland. ²⁰⁵Neuro-Imaging Genetics, QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, Queensland 4006, Australia. ²⁰⁶Cardiovascular Genetics Division, University of Utah, 420 Chipeta Way, Room 1160, Salt Lake City, Utah 84117, USA. ²⁰⁷Alzheimer Scotland Research Centre, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK. ²⁰⁸Department of Psychiatry, Erasmus Medical Center, PO Box 2040, Rotterdam, 3000 CA, The Netherlands. ²⁰⁹National Institute for Health and Welfare (THL), P.O.Box 30, Mannerheimintie 166, Helsinki, FI-00271, Finland. ²¹⁰Department of Kinesiology, Laval University, 2300 rue de la Terrasse, Quebec G1V 0A6, Canada. ²¹¹Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 N. State Street, Jackson, Mississippi 39216, USA. ²¹²Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, FI-20521, Finland. ²¹³Research Center of Applied and Preventive Cardiovascular medicine, University of Turku, Turku, FI-20521, Finland. ²¹⁴University of Groningen, University Medical Center Groningen, Department of Genetics, Hanzeplein 1, Groningen, 9700 RB, The Netherlands. ²¹⁵Department of Economics, Stockholm School of Economics, Box 6501, Stockholm, SE-113 83, Sweden. ²¹⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, Stockholm, SE-171 77, Sweden. ²¹⁷Department of Genetics and Biostatistics, Washington University School of Medicine, 4444 Forest Park Boulevard, Saint Louis, Missouri 63108, USA. ²¹⁸Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. ²¹⁹Department of Pediatrics, University of Oklahoma Health Sciences Center, 940 Stanton Young Boulevard, Oklahoma City, Oklahoma 73104, USA. ²²⁰Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA. ²²¹Sidra Medical and Research Centre, Doha, Qatar. ²²²The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, USA. ²²³Genome Institute of Singapore, 60 Biopolis Street, #02-01 Genome, Singapore, 138672, Singapore. ²²⁴Program for Personalised and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, 685 Baltimore St. MSTF, Baltimore, Maryland 21201, USA. ²²⁵Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, 685 W Baltimore MSTF, Baltimore, Maryland 21201, USA. ²²⁶BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK. ²²⁷Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, 137 E. Franklin Street, Suite 306, Chapel Hill, North Carolina 27599, USA. ²²⁸Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, Washington 98101, USA. ²²⁹Group Health Research Institute, Group Health Cooperative, 1730 Minor Ave, Suite 1360, Seattle, Washington 98101, USA. ²³⁰Imperial College Healthcare NHS Trust, Imperial College London, Praed Street, London W2 1NY, UK. ²³¹Population Health Research Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. ²³²Steno Diabetes Centre, Niels Steensens Vej 2, Gentofte, 2820, Denmark. ²³³Translational Laboratory in Genetic Medicine (TLGM), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, 138648, Singapore. ²³⁴Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK. ²³⁵Institutes for Neurogenetics and Integrative & Experimental Genomics, University of Lübeck, Lübeck 23562, Germany. ²³⁶School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India.

*These authors contributed equally to this work.



Extended Data Figure 1 | Forest plot for cognitive ability (g). Individual sub-cohort estimates of effect size and the 95% confidence interval are plotted. Sub-cohorts are ordered from top to bottom according to their weight in the meta-analysis, so larger or more homozygous cohorts appear towards the top. The scale of β_{FROH} is in intra-sex standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort names follow the conventions detailed in Supplementary Table 6 and the Supplementary Table 11 legend. Sample sizes, effect sizes and *P* values for association are given in Table 1. This trait was rank-transformed.




Extended Data Figure 2 | Forest plot for educational attainment. Individual sub-cohort estimates of effect size and the 95% confidence interval are plotted. Sub-cohorts are ordered from top to bottom according to their weight in the meta-analysis, so larger or more homozygous cohorts appear towards the top. The scale of β_{FROH} is in intra-sex standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort names follow the conventions detailed in Supplementary Table 6 and the Supplementary Table 11 legend. Sample sizes, effect sizes and *P* values for association are given in Table 1.




Extended Data Figure 3 | Forest plot for height. Individual sub-cohort estimates of effect size and the 95% confidence interval are plotted. Sub-cohorts are ordered from top to bottom according to their weight in the meta-analysis, so larger or more homozygous cohorts appear towards the top. The scale of

β_{FRDH} is in intra-sex standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort names follow the conventions detailed in Supplementary Table 6 and the Supplementary Table 11 legend. Sample sizes, effect sizes and *P* values for association are given in Table 1.




Extended Data Figure 4 | Forest plot for forced expiratory lung volume in one second. Individual sub-cohort estimates of effect size and the 95% confidence interval are plotted. Sub-cohorts are ordered from top to bottom according to their weight in the meta-analysis, so larger or more homozygous cohorts appear towards the top. The scale of β_{FRDH} is in intra-sex standard deviations. The meta-analytical estimate is displayed at the bottom. Sub-cohort names follow the conventions detailed in Supplementary Table 6 and the Supplementary Table 11 legend. Sample sizes, effect sizes and *P* values for association are given in Table 1. This trait was rank-transformed.




Extended Data Figure 5 | Signals of directional dominance are robust to stratification by geography or demographic history or inclusion of educational attainment as covariate. **a**, Cohorts are divided by continental biogeographic ancestry (African (15 sub-cohorts), East Asian (5), South and Central Asian (SC Asian; 10), Hispanic (3)), with Europeans being divided into Finns (13), other European isolates (self-declared, 23), and (non-isolated) Europeans (90). Meta-analysis was carried out for all subsets with 2,000 or more samples available. Sample numbers are as follows: cognitive *g*, Eur isolate, 6,638; European, 44,153; educational attainment, African 4,811; Eur isolate, 8,032; European, 55,549; Finland 9,068; height, African, 21,500; E Asian, 30,011; Eur isolate, 23,116; European, 228,813; Finland, 30,427; Hispanic, 5,469; SC Asian, 13,523; FEV1, African, 6,604; Eur isolate, 4,837; European, 49,223; Finland, 2,340. β_{FROH} is consistent across geography and in both isolates and more cosmopolitan populations. **b**, Cohorts were divided into high and low ROH strata of equal power and meta-analysis repeated – the effects are consistent

across strata for all four traits. The mean SROH for the high and low strata, respectively, are 13.4 and 4.3 Mb for cognitive *g*; 28.1 and 5.1 Mb for educational attainment; 31.9 and 10.8 Mb for height; and 41.4 and 4.5 Mb for FEV1. **c**, To assess the potential for socio-economic confounding, where available, educational attainment was included in the regression model (edu) and compared to a model without educational attainment (none) in the same subset of cohorts. The signals reduce slightly when the education covariate is included; the analysis is not possible for educational attainment as a trait. For cognitive *g*, numbers of subjects are 36,847 and 36,023; for height 131,614 and 120,945; and for FEV1, 15,717 and 15,425, for edu and none, respectively. The numbers differ because of missing individual educational data within cohorts. Plus signs indicate that the phenotype was rank-transformed. Trait units are intra-sex standard deviations and the genomic measure is unpruned SROH. Subset estimates of effect size for FROH and the 95% confidence are plotted.



Extended Data Figure 6 | Signals of directional dominance are robust to model choice. Meta-analytical estimates of effect size and standard errors are plotted for various models. Fixed, no mixed modelling was used; gr res, GRAMMAR+ residuals were fitted; hglm, full hierarchical generalized linear mixed model was used. Plus signs indicate that the phenotype was rank-transformed. 15,355 subjects were used for cognitive *g*, 36,060 for educational attainment, 89,112 for height and 15,262 for FEV1.



Extended Data Figure 7 | Correlation in SROH for different genotyping arrays using HapMap populations. **a–c**, *x* and *y* axes show SROH from 0–30 Mb. ill370, Illumina CNV370; aff6, Affymetrix6; ilomni, Illumina OmniExpress. The graphs are shown for the specific PLINK call parameters used. **d**, Sample numbers per continent are presented in a bar chart. AFR, African; AMR, mixed American; ASN, East Asian; EUR, European; SAN, South Asian. Only samples with SROH below 30 Mb are plotted, to be conservative to the effect of outliers, which have very strongly correlated estimates of SROH ($r = 0.96–0.97$ for comparisons including such very homozygous individuals). In these plots, the correlation between SROH called by the two arrays, $r = 0.93–0.94$.

Extended Data Table 1 | Continental ancestry of cohorts participating in each trait study.

	African	East Asian	European	Hispanic	S/C Asian	All
BMI	21689/15	29009/5	279400/117	7836/3	13464/10	351398/150
Cognitive <i>g</i>	1539/1	NA/NA	49559/22	-	-	51098/23
Diastolic BP	17074/12	24200/5	204742/85	7284/3	12876/9	266176/114
Education Attained	4811/4	NA/NA	79576/42	-	338/1	84725/47
Fasting Insulin	6895/8	1603/1	72006/49	-	6303/5	86807/63
FEV1	6604/5	617/1	58089/27	825/1	-	66135/34
FEV1/FVC	6565/5	616/1	57888/27	822/1	-	65891/34
FP Glucose	8942/9	1615/1	122368/74	1938/1	6921/5	141784/90
HbA1c	6629/4	694/1	92732/31	4038/2	7509/4	111602/42
HDL Cholesterol	15099/13	10478/5	215621/92	4426/3	12508/9	258132/122
Height	20300/14	30011/5	281369/114	5469/2	13523/10	350672/145
LDL Cholesterol	13375/11	2503/2	172245/77	4340/3	11186/8	203649/101
Systolic BP	17023/12	24424/5	205253/85	7225/3	12859/9	266784/114
Total Cholesterol	15130/13	20187/5	209421/91	4491/3	11674/8	260903/120
Triglycerides	13886/12	2542/2	181526/84	2745/2	10688/7	211387/107
Waist-hip ratio	8182/7	2549/2	171753/73	1446/1	12598/9	196528/92

The first number in each cell is the number of participants with that continental ancestry. The second number is the number of sub-cohorts. S/C Asian, South and Central Asian.